Management of toxicity in patients receiving therapy with bevacizumab
-
Published:2008-03
Issue:6
Volume:6
Page:29-39
-
ISSN:1359-6349
-
Container-title:European Journal of Cancer Supplements
-
language:en
-
Short-container-title:European Journal of Cancer Supplements
Subject
Cancer Research,Oncology
Reference45 articles.
1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004
2. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200;Giantonio;J Clin Oncol,2007
3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006
4. Bevacizumab plus combination interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial;Escudier;Lancet,2007
5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献